Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Globe Newswire•10/11/2026•07:30 ET
0
Key Highlights
- ➤XTX501 Phase 1/2 trial dosed first patient in metastatic NSCLC and select solid tumors
- ➤Xilio plans initial XTX501 Phase 1 data in fourth quarter of 2027
- ➤XTX602 IND submission planned in fourth quarter of 2027
- ➤XTX701 IND submission planned in fourth quarter of 2027
- ➤Cash runway extends into first quarter of 2028; cash totaled $122.2 million
Expert Statements
René Russo, President and Chief Executive Officer of Xilio Therapeutics
“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors”
René Russo, President and Chief Executive Officer of Xilio Therapeutics
“By incorporating masking and tumor-selective activation of a high potency, alpha-optimized IL-2 with inhibition of PD-1/PD-L1 in a single molecule, XTX501 is designed to simultaneously leverage these two validated mechanisms, while overcoming the toxicity and rapid clearance that have limited non-masked IL-2 therapies.”
René Russo, President and Chief Executive Officer of Xilio Therapeutics
“We also continued to execute across our preclinical pipeline, advancing our programs for masked, multi-specific TCEs with built-in co-stimulation toward planned IND filings next year.”
Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027
Advancing XTX602, a dual-masked CLDN18.2-targeting multi-specific TCE with co-stimulation, and XTX701, a masked PSMAxSTEAP1-targeting multi-specific TCE with co-stimulation, toward planned IND applications in the fourth quarter of 2027
Get started
Create a free account to read the full story.